Patient Centricity
Patient Centricity
Search
Our Responsibility
Human Health Our Responsibility
Research-collaboration-Gubra-obesity-treatment
Boehringer Ingelheim and Gubra enter collaboration to identify and validate targets and innovative peptides for the treatment of obesity.
1990-2023: Value through Innovation
The Boehringer Ingelheim history from 1990 to 2023, with milestones
Social innovation: catalyst for sustainable health solutions
Supporting social innovators drives sustainable health solutions in underserved communities. Learn more about Boehringer Ingelheim Social Engagements.
Disentangling fibrosis
Fibrosis is an important area of research for Boehringer Ingelheim that is focusing on fibrotic conditions of the liver, lung, kidney, skin and gut.
NEJM-IL-36-Phase-1-GPP-data
Data published in The New England Journal of Medicine show rapid improvement of symptoms in patients with a rare form of pustular psoriasis
GPP Interview with Professor Barker
An interview with Prof. Barker about generalized pustular psoriasis, its burden on patients and how patient outcomes can be improved
CT-155
Digital therapeutic
Cystic Fibrosis Genetherapy Development Option Excercise
Boehringer Ingelheim and Partners Accelerate BI 3720931 Gene Therapy as long-lasting therapeutic option for patients with cystic fibrosis
clinical-collaboration-with-Amgen
Collaboration to study Boehringer Ingelheim’s SOS1::pan-KRAS Inhibitor in combination with Amgen’s KRASG12C Inhibitor
clinical_collaboration_with_Mirati
Boehringer Ingelheim and Mirati are teaming up in a clinical collaboration to evaluate the combination of the SOS1::pan-KRAS and the selective G12C inhibitor.
Breaking prejudice in lung cancer
At Boehringer Ingelheim, addressing patient needs and fighting stigma in lung cancer care are two focus topics of the patient engagement team in oncology.
Europe needs a vibrant research eco-system
At this week's EFPIA Days in Brussels, stakeholders will discuss how to re-establish a research-friendly eco-system in Europe.
Exploring innovation in interstitial lung disease (ILD)
Interstitial lung disease (ILD) describes a group of over 200 lung disorders characterized by inflammation and scarring of the interstitium of the lungs.
The GPP Charter
The GPP Charter defines a collaborative approach to identifying common goals for the GPP community
Living with GPP
Video content showing a patient’s perspective of living with generalized pustular psoriasis (GPP), a rare skin condition
Our evolved employer value proposition
Find out from a father-daughter duo how we live up to our people promise and how our company identifies itself and differentiates from other employers.
Second cancer immunotherapy partnership with 3T Bio
Second cancer immunotherapy partnership with 3T Bio
Combatting Appetite Loss
Discover tips on how to combat appetite loss from Taking Cancer On Through Flavour
Pan-Seared Cod video
Find out how to make this delicious pan-seared cod with a fresh tomato and basil sauce from Taking Cancer on Through Flavour and Taste Life.
Collaboration-with-OxfordBioTherapeutics
Boehringer Ingelheim collaborates with Oxford BioTherapeutics to discover tumor targets to deliver first-in-class treatments for cancer patients.
collaboration-proxygen-molecular-glue-degraders
Boehringer Ingelheim collaborates with Proxygen to explore molecular glue degraders – a novel approach to fight cancer.
BI 690517 + Empagliflozin
BI 690517 + Empagliflozin: Aldosterone synthase inhibitor + SGLT2 inhibitor
Generalized pustular psoriasis is not ‘sensitive’ content
Learn about the impact that a lack of online visibility can have on people living with this chronic, inflammatory skin disease.